The recent meningitis B cluster in Canterbury has once again drawn attention to a persistent and largely structural problem in infectious disease preparedness: the inability of vaccine supply chains to respond rapidly to unanticipated surges in demand. The shortage of Bexsero (GSK) and Trumenba (Pfizer) in private pharmacy settings during the outbreak was not the result of a manufacturing failure. Instead, they reflect how vaccine markets are structurally designed1.
Understanding why shortages occur, and why they’re likely to reoccur, requires looking at three factors: biological manufacturing constraints, concentrated market dynamics, and the disconnect between public health demand and commercial supply planning.
Unlike small-molecule drugs, which are chemically synthesised and can often be scaled within relatively short timeframes, vaccines are biological products. Bexsero, for example, is a multicomponent protein-based vaccine incorporating four antigen targets derived from Neisseria menigitidis serogroup B, produced through cell cultures, purification processes and tighly regulated manufacturing systems2.
Production cycles typically take several months, with schedules set 12-18 months in advance based on forecast demand. There is no reserve capacity that can be activated in response to sudden outbreaks. Increasing supply requires additionalproduction runs, regulatory approval and batch release, meaning timelines are measured in months rather than week3.
This is not an inefficiency but a structural limitation. Any demand spike, whether driven by an outbreak or increased public awareness, will inevitably outpace supply.
The MenB vaccine market is effectively a duopoly dominated by GSK and Pfizer. This concentration reflects high development costs and scientific complexity, with Bexsero taking over two decades to reach market4.
However, once approved, vaccines operate under constrained pricing frameworks. In the UK procurement is centrally negotiated, limiting margins relative to high-value therapeutic areas such as oncology. As a result, manufacturers have little financial incentive to maintain excess production capacity beyond contracted demand5.
The outcome is a supply system optimised for efficiency rather than resilience. With only two suppliers and minimal redundancy, there is limited ability to absorb unexpected demand.
Public health demand for meningitis vaccines is relatively stable and predictable, centered on routine immunisation programmes such as the UK infant schedule introduced in 20156.
Outbreak-driven demand, however, is fundamentally different. It is localised, rapid and often concentrated in populations not covered by routine vaccination - such as adolescents or young adults. This demand sits outside standard procurement forecasts.
The Canterbury outbreak illustrates this mismatch. A sudden surge in private demand for previously unvaccinated groups created pressure on a supply chain calibrated for baseline need.
This disconnect is not accidental. Maintaining contingency stock for low-probability outbreaks is costly, and procurement systems are designed to minimise inefficiency. The consequence is that shortages emerge precisely when demand becomes more urgent.
The Canterbury case highlights a broader issue across vaccine markets. Supply chains are designed for predictable public health programmes, not acute demand shocks.
For pharmaceutical companies, the constraint is structural rather than operational. Holding excess manufacturing capacity in low-margin markets is commercially unattractive. For governments, however, the cost of under-preparedness is borne in reduced access during outbreaks.
Addressing this imbalance would require new incentive structures, such as strategic reserve contracts or public investment in surge capacity. Without such changes, similar shortages are likely to reoccur across vaccine categories.
In modern pharmaceuticals, the ability to develop effective vaccines is no longer the primary challenge. Ensuring their availability when demand spikes may be the more difficult problem.